advertisement
Abstract #5454 Published in IGR 1-2
A perspective of gene therapy in the glaucomas
Kaufman PL; Jia WWG; Tan J; Chen Z; Gabelt BT; Booth V; Tufaro F; Cynader MSurvey of Ophthalmology 1999; 43 (S1): S91-S97
Gene therapy in the anterior and posterior segment tissues may have the potential to favorably influence aqueous hydrodynamics and retinal ganglion cell biology, thereby preventing, delaying, or minimizing glaucomatous damage to the optic nerve. We demonstrated the feasibility of using a herpes viral vector (ribonucleotide reductase defective HSV-1, hrR3) to deliver the lacZ reporter gene to living cat and rat eyes. Cats received injections into the anterior chamber and rats into the vitreous cavity. In cats, lacZ expression was detectable at 1 to 2 days in the anterior outer portion of the ciliary muscle and the lining of the intertrabecular spaces of the corneoscleral and uveal meshwork. Rat eyes showed lacZ expression in the retinal pigment epithelium and photoreceptor outer segments 2 days after injection.
P.L. Kaufman, Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI; USA
Classification:
11.9 Gene therapy (Part of: 11 Medical treatment)
